Biotech firms jump on SARS bandwagon.
Basu
Paroma
P
D001709:Biotechnology / Q000191:economics* / Q000458:organization & administration / Q000639:trends*; D002170:Canada; D002681:China; D003132:Commerce; D004345:Drug Industry / Q000191:economics* / Q000379:methods / Q000458:organization & administration / Q000639:trends*; D005062:European Union; D005380:Financing, Government / Q000191:economics / Q000458:organization & administration / Q000639:trends; D006801:Humans; D011933:Reagent Kits, Diagnostic / Q000191:economics*; D012106:Research / Q000191:economics / Q000458:organization & administration / Q000639:trends; D045169:Severe Acute Respiratory Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000191:economics* / Q000517:prevention & control; D014481:United States; D014614:Vaccines, Synthetic / Q000191:economics*
D011933:Reagent Kits, Diagnostic; D014614:Vaccines, Synthetic